FTC Targets Disclosures, “Up To” And “Doctor Recommended” Claims
This article was originally published in The Tan Sheet
“A lot of research casts doubt on the effectiveness of disclosures,” says FTC official Richard Cleland. FTC will also zero in on “up-to,” “doctor recommended,” business-to-business, immunity and weight loss claims.
You may also be interested in...
Sodium phosphate laxatives linked to SAERs; FTC scrutinizes personalized supplement claims; NAD refers Xlear LLC to FTC; ChromaDex inks marketing deal with 5LINX; CVS launches vitamin sales, info hub on its website; Star Scientific shareholder suit proceeds.
FTC settles with Sensa products and three other weight-loss product marketers, and launches its “gut check” voluntary media partnership program to prevent bogus claims. A firm cited in FTC’s 2011 investigation of human chorionic gonadotropin product ads also reached a settlement with the agency.
Revised online advertising disclosure guidelines detail FTC’s expectations for how advertisers should craft disclosures in the world of social media and mobile devices.